The Lancet. Published Online December 22, 2016 http://dx.doi.org/10.1016/S0140-6736(16)32621-6. Open Access
The Road to Recovery. This synthesis report is based on three national studies on the evolution of the Ebola epidemic and its impact on Guinea, Liberia and Sierra Leone
Eur Respir J 2014; 43: 24–35 | DOI: 10.1183/09031936.00113413
The document contains preliminary report on all aspects of WHO’s response in the Ebola outbreak. WHO Member States will discuss the report at the sixty-eighth World Health Assembly.
The objectives of the meeting were to agree on coordinated and aligned support to the 3 countries’ national health recovery plans (Guinea, Liberia, Sierra Leone); to identify cross-cutting areas and opportunities for integration; to identify ways to improve implementation modalities; and to identi...fy actions including technical assistance needed to support the countries in the process of building resilient health systems.
The outcomes of the meeting consisted in proposed country action plans to move forward with the implementation of the recovery plans. The action plans includes:priorities and areas of work; activities needed to improve implementation modalities; technical assistance needs.
more
The context of the Ebola epidemic presented extreme challenges for Oxfam, as it did for many organisations. At the onset of the epidemic, there was a general lack of understanding of the disease and how to respond to it effectively and safely. A pervasive and persistent climate of fear, coupled with... changing predictions about the likely evolution of the epidemic, influenced analysis and response at all levels. There was strong pressure to treat the epidemic as a medical emergency requiring a medical response – organised through topdown processes – rather than standard humanitarian coordination
more
The third report in the series Resources for Results published by the UN Office of the Special Envoy on Ebola provides an overview of resources announced and disbursed to countries and agencies as of 31 January 2015. This report is a next step towards more transparency allowing all, especially the g...overnments in the affected countries, to effectively manage and better utilize the available resources
more
The Handbook on Law and Disaster Risk Reduction (the Handbook) has been developed to provide guidance on how to use the Checklist and conduct related legislative reviews and reform processes. While the methodology for using the Checklist needs to be tailored to each country’s context and respectiv...e needs, the Handbook is intended to provide general guidance on key steps to consider.
more
The new five-year agenda of WHO in Africa, The Africa Health Transformation Programme, 2015–2020: a vision for universal health coverage, is the strategic framework that will guide WHO’s contribution to the emerging sustainable development platform in Africa. It articulates a vision for health a...nd development that aims to address the unacceptable inequalities and inequities that have kept our region lagging far behind others in terms of health indices and enjoyment of the highest attainable standard of life.
more
Series on Disability-Inclusive Development. This publication introduces the key concepts for disability-inclusive development and highlights practical examples by CBM, to contribute to the dialogue on disability-inclusive development
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
An Independent Report
of the West Africa Commission on Drugs
Conceived as part of the CWS-A/P project on regional security and risk management, this book presents a
collection of testimonies from aid workers in some of the most insecure and volatile environments in the world.
The participants recount a broad array of security incidents, such as kidnappings,... suicide bombings, mob
violence, road ambushes, and point-blank range shootings. Their narrative provides valuable information on
how organizations can manage security risks and streamline safety policies.
more
The International Pharmaceutical Federation (FIP) is a global federation of national associations of pharmacists and
pharmaceutical scientists. In order to support these associations in their fight against AMR, FIP has prepared this
briefing document. It is an overview of the different activities ...that community and hospital pharmacists are involved
into prevent AMR and to reverse AMR rates.
more
The ECDC, the EFSA and the EMA have for the first time jointly explored associations between consumption of antimicrobials in humans and food-producing animals, and antimicrobial resistance in bacteria from humans and food-producing animals, using 2011 and 2012 data currently available from their re...levant five EU monitoring networks. Combined data on antimicrobial consumption and corresponding resistance in animals and humans for EU MSs and reporting countries were analysed using logistic regression models for selected combinations of bacteria and antimicrobials. A summary indicator of the proportion of resistant bacteria in the main food-producing animal species was calculated for the analysis, as consumption data in food-producing animals were not available at the species level
more